Biotech

All Articles

Regeneron's Opdualag opponent shows 57% response price

.Regeneron is actually back with long-term follow-up for its LAG-3 inhibitor and also PD-1 inhibitor...

AstraZeneca blog posts data on in-house rivals to AbbVie, Pfizer ADCs

.AstraZeneca has discussed a very early take a look at the efficiency of its internal antibody-drug ...

iTeos- GSK's TIGIT star shows purposeful improvement

.After announcing a period 3 launch based upon beneficial midstage end results, iTeos and GSK are la...

More collaborative FDA may accelerate rare ailment R&ampD: record

.The FDA needs to be actually more available as well as joint to let loose a rise in commendations o...

Zenas, MBX, Bicara scalp to Nasdaq in warm day for biotech IPOs

.It's an abnormally occupied Friday for biotech IPOs, with Zenas BioPharma, MBX and Bicara Therapies...

Atea's COVID antiviral stops working to halt hospital stays in stage 3

.Atea Pharmaceuticals' antiviral has fallen short another COVID-19 trial, but the biotech still stor...

Neurocrine's quote to spare schizophrenia prospect fails

.Neurocrine Biosciences' mental illness system pivot has actually stopped working. The biotech was a...

Sanofi pays $110M upfront for late-stage radioligand therapy

.Sanofi has actually made an overdue entry to the radioligand celebration, paying out one hundred th...

F 2G increases $100M for second attempt to obtain new antifungal to market

.After F2G's first try to get a brand-new training class of antifungal to market was derailed due to...

Moderna targets $1.1 B in R&ampD investing cuts, drops 5 plans among profitability stress

.Moderna has pledged to cut R&ampD spending through $1.1 billion through 2027. The selection to shri...